Preliminary Anti-tumour Activity of mTor Kinase Inhibitor in Advanced Tumours

Summary

To investigate the safety and tolerability of AZD8055 intermittent dosing schedules when given orally to patients with advanced solid malignancies and lymphomas. Two intermittent dosing schedules will be explored with increasing doses until a maximum tolerated dose is determined for each schedule.

Timeline

Start

—

Primary completion

—

Completion

—

Outcome

Outcome not reported

Stopped: “Amendment to study compound development programme”

Drugs

Indications